Tony Kingsley
Chief Executive Officer bei Stablix, Inc.
Profil
Stuart Anthony Kingsley currently works at Stablix, Inc., as Chief Executive Officer from 2022 and Annovation BioPharma, Inc., as President & Director.
Mr. Kingsley also formerly worked at TARIS BioMedical LLC, as President, Chief Executive Officer & Director in 2019, Scholar Rock, Inc., as President, Chief Executive Officer & Director from 2020 to 2021, Scholar Rock Holding Corp., as President, Chief Executive Officer & Director from 2020 to 2021, Third Wave Technologies, Inc., as Director in 2008, Proteon Therapeutics, Inc., as Independent Director from 2015 to 2019, Hologic, Inc., as Senior VP & GM-Gynecological Surgical Products in 2009, Biogen, Inc., as Head-Global Commercial Operations from 2011 to 2016, Cytyc Corp., as President-Diagnostic Products Division & Senior VP in 2007, The Medicines Co., as President & Chief Operating Officer from 2016 to 2017, and McKinsey & Co., Inc., as Partner in 2006.
Mr. Kingsley received his undergraduate degree from Dartmouth College and Masters Business Admin degree from Harvard Business School.
Aktive Positionen von Tony Kingsley
| Unternehmen | Position | Beginn |
|---|---|---|
Stablix, Inc.
 Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Chief Executive Officer | 14.02.2022 |
Annovation BioPharma, Inc.
 Annovation BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Annovation BioPharma, Inc. develops pharmaceutical products in the field of anesthesia, sedation and sleep. It is developing a rapid-acting anesthesia called Rapidate. The firm's novel agents are designed to allow more precise control of anesthesia and enable safer treatment of patients undergoing surgical procedures. The company was founded in 2009 by Nicholas Barker and is headquartered in Parsippany, NJ. | President | - |
Ehemalige bekannte Positionen von Tony Kingsley
| Unternehmen | Position | Ende |
|---|---|---|
Scholar Rock, Inc.
 Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Chief Executive Officer | 03.08.2021 |
| SCHOLAR ROCK HOLDING CORPORATION | Chief Executive Officer | 29.07.2021 |
TARIS BioMedical LLC
 TARIS BioMedical LLC Pharmaceuticals: MajorHealth Technology TARIS BioMedical LLC operates as a clinical-stage pharmaceutical company. It specializes in urology, continuous local dosing, bladder diseases, oncology, voiding dysfunction. The company was founded by Robert S. Langer Jr., Christine Bunt, and Michael J. Cima in 2008 and is headquartered in Lexington, MA. | Chief Executive Officer | 31.12.2019 |
| PROTARA THERAPEUTICS, INC. | Director/Board Member | 15.04.2019 |
| THE MEDICINES COMPANY | President | 29.12.2017 |
Ausbildung von Tony Kingsley
| Dartmouth College | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| HOLOGIC, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Cytyc Corp.
 Cytyc Corp. Medical SpecialtiesHealth Technology Cytyc Corp. manufactures and markets medical diagnostic applications. The company is headquartered in Marlborough, MA. | Health Technology |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Third Wave Technologies, Inc.
 Third Wave Technologies, Inc. BiotechnologyHealth Technology Third Wave Technologies, Inc. developed DNA and RNA detection technology. It provided molecular solutions for clinical, research, and agricultural customers. The company was founded in February 1993 and was headquartered in Madison, WI. | Health Technology |
Proteon Therapeutics, Inc.
 Proteon Therapeutics, Inc. BiotechnologyHealth Technology Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001 and is headquartered in Waltham, MA. | Health Technology |
TARIS BioMedical LLC
TARIS BioMedical LLC Pharmaceuticals: MajorHealth Technology TARIS BioMedical LLC operates as a clinical-stage pharmaceutical company. It specializes in urology, continuous local dosing, bladder diseases, oncology, voiding dysfunction. The company was founded by Robert S. Langer Jr., Christine Bunt, and Michael J. Cima in 2008 and is headquartered in Lexington, MA. | Health Technology |
Annovation BioPharma, Inc.
Annovation BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Annovation BioPharma, Inc. develops pharmaceutical products in the field of anesthesia, sedation and sleep. It is developing a rapid-acting anesthesia called Rapidate. The firm's novel agents are designed to allow more precise control of anesthesia and enable safer treatment of patients undergoing surgical procedures. The company was founded in 2009 by Nicholas Barker and is headquartered in Parsippany, NJ. | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Health Technology |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Commercial Services |
